NewsLEON appoints Dr. Setu Kasera as Chief
Scientific Officer••leon-nanodrugs GmbH (LEON) is a leading developer of innovative nano-encapsulation
devices, seamlessly scalable from R&D to GMP market supply
New CSO to drive client-oriented product R&D and focus the Company’s efforts oncompletion of product development and preparation for market readinessleon-nanodrugs GmbH (“LEON”), a disrupting enabler of nanotechnology for the pharmaceuticalindustry, today announced the appointment of Dr. Setu Kasera as Chief Scientific Officer, effectiveMay 15, 2023. Since October 2022, Dr. Kasera has been driving the development of LEON’s devices as
Head of Science and Engineering to put the proprietary technology to practice, while the Company
has increased the pace of product development to get it across the finishing line. Dr. Setu Kasera
succeeds Dr. Frank Stieneker, who developed the core of LEON’s innovative reactor technology for its
GMP-tailored devices. He will continue to support the Company as an exclusive advisor.
Dr. Robert Becker, chairman of the LEON Supervisory Board, said: “Setu has hands-on experience innanotechnology, and has already taken a leading role in bringing our technology to application. AsCSO, Setu will continue the development of LEON’s devices to completion and tailor the productoffering to LEON’s target groups. I also express my sincere gratitude to Frank Stieneker, who has beena vital driver in the development of LEON’s ingenious reactor technology and who has significantly
contributed to LEON’s strategic outline. We are very pleased that we will continue to work with him
and can count on his expertise and support in his new advisory role.”“Conceiving LEON’s technology and, together with the team, putting theory to practice by realizing
the FR-JET reactor, which now serves as a core piece of LEON’s manufacturing devices, was a truly
rewarding experience,” commented Dr. Frank Stieneker. “As I will continue to advise and support
LEON in the future, I look forward to seeing the potential of LEON’s devices unfold and revolutionize
the manufacturing of nanomedicines and ultimately, enhance access for patients.”
Dr. Setu Kasera, CSO of LEON, added: “Managing the implementation of the FR-JET technology andseeing its performance first-hand, I can only underline that LEON’s encapsulation devices are certain
to cause a disruptive impact in the R&D and GMP-manufacturing of nanomedicines. I take great
pleasure in continuing to direct the development of LEON’s devices and in facilitating the adaptationof this advanced technology to the processes of our business partners and clients, finally accelerating
the timeline from drug development to patient.”
Dr. Setu Kasera joined LEON as Head of Science and Engineering and has been a strong team lead anddriver of the progress of LEON’s research projects. She has strong expertise in nanotechnology fromher R&D work at the University of Cambridge and independent research projects, together with solid
experience in pharma operations and CMC (chemistry, manufacturing and controls). In variousinternational in-house and consulting roles in the health industry she has gained capabilities inmanagement, strategy and business development. Dr. Setu Kasera received her MPhil and her PhD in
chemistry from the University of Cambridge, UK, for her research in nanotechnology.
LEON's product platform is built on the Company’s proprietary innovative FR-JET Technology thatenables a major efficiency improvement in the formulation process of active ingredients intonanodrug carriers such as lipid nanoparticles (LNPs). LEON's devices, NANOme and NANOus, aredesigned for aseptic processing, GMP compliance and quick scale-up. NANOme is optimized for smallscale individual patient and clinical trial-size production. NANOus is a fully automated, aseptic device
enabling the LNP-encapsulation of active pharmaceutical ingredients (APIs) from medium to large
scale with high throughput using process analytical technology (PAT).

ABOUT LEON-NANODRUGS
leon-nanodrugs GmbH (“LEON”) is a pharmatech company specializing in the development andmarketing of devices for the encapsulation of genetic material and other active substances into
nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its
innovative solutions based on its proprietary FR-JET Technology, enabling pharma companies andsmall biotechs as well as CDMOs to optimize nanomedicine manufacturing and take full advantage ofthe significant progress being made in advanced therapies.
LEON's GMP-compliant, aseptic devices NANOme and NANOus increase efficiency in the productionof nano drug carriers and are suitable for both clinical-scale and commercial production. In addition
to its product offering, LEON will provide in-house lab capacity for process development with its owndevices.
For further information, please visit https://leon-nanodrugs.com/ and follow us on LinkedIn andTwitter.

Dr. Setu Kasera, CSO of leon-nanodrugs GmbH